Check-Cap (NASDAQ:CHEK) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Tuesday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

Shares of CHEK stock opened at $2.22 on Tuesday. The stock’s 50-day simple moving average is $2.25 and its 200-day simple moving average is $2.57. The firm has a market capitalization of $12.99 million, a PE ratio of -0.74 and a beta of 0.28. Check-Cap has a fifty-two week low of $1.27 and a fifty-two week high of $4.63.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.